Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 18:8:13-17.
doi: 10.1016/j.jbo.2017.08.003. eCollection 2017 Sep.

Complications of bone metastases from malignant melanoma

Jamal Zekri  1   2 , Maria Marples  3 , Dominic Taylor  3 , Kiran Kandukurti  1 , Lucy McParland  4 , Janet E Brown  5
Affiliations

Complications of bone metastases from malignant melanoma

Jamal Zekri et al. J Bone Oncol. .

Abstract

Introduction: Metastatic bone disease (MBD) carries significant morbidity for patients with cancer. MBD from malignant melanoma (MM) is understudied. We examined the characteristics, morbidity, management and outcome of MBD in patients with MM.

Methods: Patients with metastatic MM managed at two referral cancer centres in England were identified. Those with bone metastases (BMs) were selected. Patient and disease characteristics including skeletal related events (SREs) were extracted from medical records. The Kaplan Meier method was used to calculate median survival.

Results: Five hundred and eighteen patients with metastatic MM were managed between years 2000 and 2008. Eighty nine (17.2%) patients had BMs and are the subject of this study. Median age at diagnosis was 53 years and 55% were males. BMs were identified at the time of diagnosis of metastatic disease in 68.5% patients. Sixty-six (74.2%) had multiple bone lesions and 80.9% had axial skeleton involvement. One hundred and twenty nine skeletal related events occurred in 59 (66.3%) patients (50 radiotherapy, 28 hypercalcaemia, 20 bone fractures, 18 spinal cord compression and 13 orthopaedic surgery). The annual skeletal morbidity rate was 2.5. Median survival from diagnosis of BMs was 17.3 weeks and was 5.6 weeks from the first episode of hypercalcaemia.

Conclusion: MBD affects a clinically important proportion (17.2%) of patients with metastatic MM. It carries a substantial morbidity and mortality exceeding that caused by BMs from breast and prostate cancer. These patients should receive the currently licensed bone modifying agents and should be included in clinical trials addressing MBD.

Keywords: Bone metastases; Melanoma; Skeletal related events.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of 129 reported skeletal related events.
Fig. 2
Fig. 2
Overall survival in weeks from diagnosis of bone metastases.
See this image and copyright information in PMC

References

    1. Jemal A., Saraiya M., Patel P., Cherala S.S., Barnholtz-Sloan J., Kim J., Wiggins C.L., Wingo P.A. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J. Am. Acad. Dermatol. 2011;65:S17–S25–3. (doi:10.1016/j.jaad.2011.04.032) - PubMed
    1. Dequen P., Lorigan P., Jansen J.P., van Baardewijk M., Ouwens M.J., Kotapati S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist. 2012;17:1376–1385. - PMC - PubMed
    1. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., Urist M., McMasters K.M., Ross M.I., Kirkwood J.M., Atkins M.B., Thompson J.A., Coit D.G., Byrd D., Desmond R., Zhang Y., Liu P.Y., Lyman G.H., Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001;19:3622–3634. - PubMed
    1. Karim S.M., Brown J., Zekri J. Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. Clin. Adv. Hematol. Oncol. 2013;11:281–287. - PubMed
    1. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006;12:6243s–6249s. - PubMed